Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER | Zendy

Zafar Sharif | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER

Author(s) -

Zafar Sharif

Publication year - 2008

Publication title -

patient preference and adherence

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.885

H-Index - 48

ISSN - 1177-889X

DOI - 10.2147/ppa.s3346

Subject(s) - medicine , paliperidone palmitate , schizophrenia (object oriented programming) , paliperidone , antipsychotic , psychiatry , population , clinical trial , intensive care medicine , placebo , pharmacology , alternative medicine , pathology , environmental health

Antipsychotic medications provide the foundation for treatment of acute exacerbations as well as relapse prevention in patients with schizophrenia as demonstrated by rigorous placebo-controlled trials. However, despite their proven effectiveness, poor adherence to prescribed antipsychotic regimens remains the most important driver of suboptimal clinical outcomes in this population. This paper reviews the magnitude of the problem of medication non-adherence in patients with schizophrenia and the various factors that contribute to non-adherence, with particular emphasis on factors related to antipsychotic medications. The profile of the latest atypical antipsychotic, paliperidone extended-release (ER) tablets, is then reviewed and the implications of its unique pharmacokinetic profile for adherence in this patient population are discussed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research